DK0571474T3 - Orthomolekylær fremgangsmåde til behandling af seglcellesygdom - Google Patents

Orthomolekylær fremgangsmåde til behandling af seglcellesygdom

Info

Publication number
DK0571474T3
DK0571474T3 DK92904928T DK92904928T DK0571474T3 DK 0571474 T3 DK0571474 T3 DK 0571474T3 DK 92904928 T DK92904928 T DK 92904928T DK 92904928 T DK92904928 T DK 92904928T DK 0571474 T3 DK0571474 T3 DK 0571474T3
Authority
DK
Denmark
Prior art keywords
orthomolecular
treatment
sickle cell
cell disease
disease
Prior art date
Application number
DK92904928T
Other languages
Danish (da)
English (en)
Inventor
Michael Wilburn
Original Assignee
Michael Wilburn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Wilburn filed Critical Michael Wilburn
Application granted granted Critical
Publication of DK0571474T3 publication Critical patent/DK0571474T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK92904928T 1991-02-08 1992-01-31 Orthomolekylær fremgangsmåde til behandling af seglcellesygdom DK0571474T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/652,773 US5108754A (en) 1991-02-08 1991-02-08 Orthomolecular method of treating sickle cell disease
PCT/US1992/000450 WO1992013522A1 (en) 1991-02-08 1992-01-31 Orthomolecular method of treating sickle cell disease

Publications (1)

Publication Number Publication Date
DK0571474T3 true DK0571474T3 (da) 1999-08-30

Family

ID=24618098

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92904928T DK0571474T3 (da) 1991-02-08 1992-01-31 Orthomolekylær fremgangsmåde til behandling af seglcellesygdom

Country Status (15)

Country Link
US (1) US5108754A (enExample)
EP (1) EP0571474B1 (enExample)
JP (1) JPH06507382A (enExample)
KR (1) KR100221118B1 (enExample)
AP (1) AP275A (enExample)
AT (1) ATE175204T1 (enExample)
AU (1) AU662124B2 (enExample)
BR (1) BR9205609A (enExample)
CA (1) CA2103580C (enExample)
DE (1) DE69228054T2 (enExample)
DK (1) DK0571474T3 (enExample)
ES (1) ES2125887T3 (enExample)
GR (1) GR3029742T3 (enExample)
IL (1) IL100663A (enExample)
WO (1) WO1992013522A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
HUT72422A (en) * 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
KR20020088498A (ko) * 2001-05-17 2002-11-29 (주)미토콘 에스-아데노실메티오닌을 유효성분으로 함유하는 인슐린저항증 개선용 조성물
DE10243234A1 (de) * 2002-09-17 2004-03-25 Phenion Gmbh & Co. Kg Tocopherylester
WO2005004884A2 (en) * 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
EP4063481A1 (en) * 2014-07-30 2022-09-28 Case Western Reserve University Biochips to diagnose hemoglobin disorders and monitor blood cells
CA2963819A1 (en) 2014-10-08 2016-04-14 Epigenetics Pharma Llc Vitamin e-nucleoside prodrugs
WO2016196281A1 (en) * 2015-06-01 2016-12-08 Nanometics Llc Mtap inhibitors for the treatment of sickle cemtap disease
AU2017324053B2 (en) 2016-09-08 2020-08-06 Hemex Health, Inc. Diagnostics systems and methods
US10349589B2 (en) 2016-09-08 2019-07-16 Hemex Health, Inc. Diagnostics systems and methods
KR20190092778A (ko) 2018-01-31 2019-08-08 양원용 태양광을 이용한 기능성 전동식 농약분무기
WO2020264182A1 (en) 2019-06-25 2020-12-30 Hemex Health, Inc. Diagnostics systems and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57609A (en) * 1979-06-21 1983-05-15 Yeda Res & Dev Pharmaceutical compositions for the treatment of sickle cell disease comprising p-nitrobenzyl esters or amides of aromatic or hydrophobic aminoacids
US4612194A (en) * 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease

Also Published As

Publication number Publication date
IL100663A0 (en) 1992-09-06
KR100221118B1 (ko) 1999-09-15
EP0571474A4 (enExample) 1994-02-09
ES2125887T3 (es) 1999-03-16
IL100663A (en) 1995-10-31
US5108754A (en) 1992-04-28
AU662124B2 (en) 1995-08-24
EP0571474A1 (en) 1993-12-01
AU1250592A (en) 1992-09-07
WO1992013522A1 (en) 1992-08-20
BR9205609A (pt) 1994-07-26
CA2103580A1 (en) 1992-08-09
AP275A (en) 1993-07-18
CA2103580C (en) 2002-11-26
JPH06507382A (ja) 1994-08-25
GR3029742T3 (en) 1999-06-30
EP0571474B1 (en) 1998-12-30
ATE175204T1 (de) 1999-01-15
DE69228054D1 (de) 1999-02-11
DE69228054T2 (de) 1999-08-05
AP9200358A0 (en) 1992-04-30

Similar Documents

Publication Publication Date Title
DK0730864T3 (da) Lægemiddel til behandling af inflammatoriske hjertesygdomme
DK186688D0 (da) Fremgangsmaade til dyrkning af leukocytter
DK36491D0 (da) Praeparat til behandling af erektiv dysfunktion
FI890130A0 (fi) Anordning vid framstaellning av ett intravenoest filter foer implantation.
DK198588A (da) Fremgangsmaade til behandling af spildevand
DK176487D0 (da) Middel til behandling af inflammationer i oejet
FI905124A0 (fi) Menetelmä pyrimidiinien valmistamiseksi
FI912335A0 (fi) Foerfarande foer framstaellning av rikligt med fastaemnen innehaollande uppslamningar.
DK447489A (da) Metode til stabilisering af blod
BR9205609A (pt) Processo ortomolecular de tratamento de doença falciforme
FI894924A7 (fi) Menetelmä 5-substituoitujen 3-furaldehydien valmistamiseksi
DK162806C (da) Fremgangsmaade til bedoevelse af lungeaandende slagtedyr
DK524489A (da) Fremgangsmaade til fremstilling af biologisk aktive forbindelser, specielt enzymer
DK101197A (da) Medikament til behandling af thrombocytopenia
DK39789A (da) Fremgangsmaade til fremstilling af n-phosphonmethyliminodieddikesyre
DK281590A (da) Fremgangsmaade til regenereringsbehandling af overvejende lerbundet stoeberigammelsand
DK0458855T3 (da) Farmaceutisk præparat til behandling af tonsillitis
DK0519512T3 (da) Mikrobiologisk fremgangsmåde til fremstilling af 5-hydroxypyrazincarboxylsyre
DK0546906T3 (da) Ny fremgangsmåde til fremstilling af 4-amino-5-hexensyre
FI892144A7 (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
DK0553792T3 (da) Fremgangsmåde til fremstilling af dinatriumsalt,hemiheptahydratet af cefriaxon
DK72288A (da) Farmaceutisk praeparat til behandling af ulcerativ tyktarmssygdom
FI910662A7 (fi) Menetelmä 7-amino-3-metoksimetyyli-kef-3-emi-4-karboksyylihapon valmistamiseksi
NO904496L (no) Fremgangsmaate for fremstilling av optisk aktive tiazetokinolin-3-karboksylsyreforbindelser.
ATE137592T1 (de) Vorblitz-me methode